News

Prestige Biopharma Partners with Biosidus for Tuznue® Launch

Prestige Biopharma Partners with Biosidus for Tuznue® Launch

Prestige Biopharma and Biosidus Forge Strategic Alliance

SINGAPORE — Prestige Biopharma, a forward-thinking biopharmaceutical entity focusing on antibody therapies, has recently collaborated with Biosidus, an established biotechnology firm based in Argentina. This partnership comes with an exclusive licensing and supply agreement aimed at promoting Tuznue® (trastuzumab) throughout various Latin American countries.

About Tuznue® and Its Significance

Tuznue® serves as a biosimilar to Herceptin® (trastuzumab), a well-known medication utilized in the management of breast cancer and metastatic gastric cancer. In a significant step for the company, Prestige Biopharma obtained marketing approval from the European Commission for Tuznue® in September 2024. This pivotal approval signifies not just an achievement for the firm but also a broader movement toward making affordable treatment options available on a global scale.

Exclusive Marketing Rights Granted to Biosidus

Under the terms of their agreement, Biosidus has obtained the exclusive rights to distribute and market Tuznue® in key markets, including Argentina, Mexico, Bolivia, and Paraguay. Their extensive commercial connections and expertise in biosimilar integration position them as a suitable partner for this venture. Meanwhile, Prestige Biopharma will handle the production and supply of the drug from its top-notch, EU-GMP-certified manufacturing facility.

Statements from Leadership

Lisa S. Park, CEO of Prestige Biopharma, expressed enthusiasm about the collaboration: "This strategic partnership with Biosidus empowers us to further our mission in Argentina and other vital Latin American markets. We believe that with their strong regional foothold, we can effectively introduce our leading biosimilar to the healthcare community."

Mariano Elizalde, CEO of Biosidus, also shared his excitement: "Working together with Prestige Biopharma allows us to boost our portfolio of biosimilars and underlines our dedication to providing biotech medicines across Latin America. Our collaboration opens new possibilities for patients and healthcare providers alike, establishing Tuznue® as a viable option."

Understanding Tuznue® in More Detail

Tuznue® stands out as a cost-efficient alternative to the brand-name Herceptin® (trastuzumab), offering similar effectiveness and safety standards. It caters to patients suffering from conditions like HER2-positive metastatic breast cancer and HER2-positive gastric cancer, thereby expanding treatment accessibility.

A Closer Look at Prestige Biopharma

Founded in 2015, Prestige Biopharma has carved a niche for itself in the biopharmaceutical industry. The company boasts a wide-ranging product lineup that includes pioneering antibody medications and various vital biosimilars currently undergoing clinical evaluation. One prominent candidate is ulenistamab, a next-generation antibody treatment that has received numerous designations to facilitate its progress through clinical phases.

About Biosidus and Its Legacy

Biosidus has a remarkable legacy, being a trailblazer in the biotechnology sector for over 42 years. It has successfully established a strong presence in Latin America and is increasingly recognized in emerging markets such as Asia and Africa. Their commitment lies in delivering high-quality biopharmaceutical products at competitive prices to elevate healthcare standards in their regions.

Frequently Asked Questions

What is the significance of the Tuznue® agreement?

The agreement allows for the effective commercialization of Tuznue® across Latin America, increasing access to treatment for patients.

Who is Prestige Biopharma?

Prestige Biopharma is a biopharmaceutical company focused on developing antibody therapeutics and biosimilars.

What is Tuznue®?

Tuznue® is a biosimilar to Herceptin® and is indicated for the treatment of certain types of breast and gastric cancers.

Where will Tuznue® be marketed?

Biosidus will market Tuznue® in Argentina, Mexico, Bolivia, and Paraguay.

What is the role of Biosidus in this partnership?

Biosidus will manage the marketing and distribution of Tuznue® while also manufacturing the drug for local and export markets.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 125

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 114

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 515

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 158

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 65

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading

Top 5 Most Recently Viewed Articles

The Hiring Crisis for Gen Z: Understanding Key Economic Factors

Updated Category News Views 472

The Hiring Crisis for Gen Z In today's economy, young Americans, particularly those under 25, are experiencing a significant challenge in securing employment. This issue, marked by increasing unemployment rates among recent graduates, is creating alarm. Most agree that the factors influencing this crisis point to a stagnation in hiring practices rather than advancements...

Continue Reading
Recent Class Action Highlights Concerns Around Bumble Inc. Shares

Updated Category News Views 78

Understanding the Recent Class Action Against Bumble Inc. The landscape of online dating and social networking continues to evolve, with Bumble Inc. playing a significant role in shaping user experiences. Recently, a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Bumble Inc. (BMBL). This...

Continue Reading
Analyzing Li Auto Inc's Market Sentiment and Short Interest

Updated Category News Views 165

Understanding Market Sentiment for Li Auto Inc Li Auto Inc (NYSE: LI) has recently witnessed a noteworthy shift in its short interest percentage. As reported, the company’s short interest has decreased by 13.66%, with approximately 20.65 million shares being sold short. This figure represents about 5.12% of the total shares that are available for trading. The data...

Continue Reading
Equity Markets Take a Breather During Holiday Pause

Updated Category News Views 245

Markets Hold Steady as Investors Reflect With the US markets taking a break for the Thanksgiving holiday, global equities have collectively paused for a moment of reflection. This calmness among investors is primarily influenced by current expectations regarding a dovish shift in Federal Reserve policy. Speculation is high, with many assigning about an 80% probability for...

Continue Reading
University of Phoenix's New Leadership in Counseling: What’s Next?

Updated Category News Views 358

New Leadership Spotlight: Yurandol Thompson Elevated The University of Phoenix has gone and done it again, appointing Yurandol Thompson as Associate Dean for Counseling, effective January 29, 2026. Now, this isn’t just any old shake-up. Dr. Thompson brings over a decade of experience in clinical operations and programmatic excellence. I mean, come on—sounds impressive...

Continue Reading